Charles River Laboratories: Frontage Bioanalysis And DMPK Acquisition Valued At Up To $545 Million
· pulse2.com · popularity 21/100 · 0 similar stories today · Entrepreneurship & Startups (Business & Finance)
Read the original at pulse2.com →
Summary
Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and drug metabolism and pharmacokinetics businesses in Exton, Pennsylvania, for approximately $470 million in cash, with additional payments of up to $75 million contingent on future performance. The transaction could therefore reach approximately $545 million and will expand Charles River's clinical bioanalysis capabilities. The post Charles River Laboratories: Frontage Bioanalysis And DMPK Acquisition Valued At Up To $545 Million appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 2.